Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Affimed GmbH
Alfasigma SpA
Angiocrine Bioscience Inc
Apollomics Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chimeric Therapeutics Ltd
CSL Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eutilex Co Ltd
Faron Pharmaceuticals Oy
Genentech USA Inc
Gibson Oncology LLC
Gilead Sciences Inc
Glenmark Pharmaceuticals Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Helocyte Biosciences Inc
HRAIN Biotechnology Co Ltd
Hutchison MediPharma Ltd
Immune Cell Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
Inhibrx Inc
Innovent Biologics Inc
Intellia Therapeutics Inc
Kymera Therapeutics Inc
LegoChem Biosciences Inc
Luye Pharma Group Ltd
Magenta Therapeutics Inc
Marker Therapeutics Inc
MediSix Therapeutics Pte Ltd
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec BV & Co KG
Mirati Therapeutics Inc
NewBio Therapeutics Inc
Northlake International LLC
OncoTartis Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PlantForm Corp
Protheragen Inc
Rafael Pharmaceuticals Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
Seagen Inc
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Suzhou Everhealth Biomedical Co Ltd
Syndax Pharmaceuticals Inc
Tacitus Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tessa Therapeutics Ltd
Tevogen Bio Inc
Tubulis GmbH
Tyme Inc
Vincerx Pharma Inc
Viracta Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles
(nivolumab + relatlimab) – Drug Profile
(pembrolizumab+vibostolimab) – Drug Profile
AB-205 – Drug Profile
acalabrutinib maleate – Drug Profile
ADCAVP-10 – Drug Profile
AFM-13 – Drug Profile
amdizalisib – Drug Profile
AN-4005 – Drug Profile
Antibody to Inhibit PD-L1 for Oncology – Drug Profile
APL-502 – Drug Profile
avelumab – Drug Profile
AZD-4573 – Drug Profile
AZD-7789 – Drug Profile
B-006 – Drug Profile
bendamustine hydrochloride – Drug Profile
bexmarilimab – Drug Profile
BMS-986415 – Drug Profile
BP-1002 – Drug Profile
brentuximab vedotin – Drug Profile
CA-170 – Drug Profile
CAL-1 – Drug Profile
camidanlumab tesirine – Drug Profile
CAT-03106 – Drug Profile
CAT-12-106 – Drug Profile
CB-103 – Drug Profile
CBM-C30.1 – Drug Profile
CD3XCD20 bsAb – Drug Profile
Cellular Immunotherapy for Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma – Drug Profile
Cellular Immunotherapy for Oncology – Drug Profile
Cellular Immunotherapy to Target CD56 for Oncology – Drug Profile
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Epstein-Barr Virus Associated Cancers – Drug Profile
Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology – Drug Profile
cemiplimab – Drug Profile
CHM-0201 – Drug Profile
copanlisib hydrochloride – Drug Profile
cosibelimab – Drug Profile
CT-900 – Drug Profile
CTL-19 – Drug Profile
CXD-101 – Drug Profile
CYNK-001 – Drug Profile
devimistat – Drug Profile
durvalumab – Drug Profile
durvalumab + tremelimumab – Drug Profile
EBViNT – Drug Profile
entinostat – Drug Profile
enzalutamide – Drug Profile
F-0002ADC – Drug Profile
fimepinostat – Drug Profile
FLX-475 – Drug Profile
Gene Therapy 1 for Oncology – Drug Profile
Gene Therapy for Hodgkin Lymphoma, Non Hodgkin's Lymphoma and Plasma Cell Neoplasm – Drug Profile
Gene Therapy to Target CD19 and CD30 for Hodgkin Lymphoma – Drug Profile
Gene Therapy to Target CD19 for Oncology – Drug Profile
Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas – Drug Profile
Gene Therapy to Target CD30 for Blood Cancer – Drug Profile
Gene Therapy to Target CD30 for Blood Cancers – Drug Profile
Gene Therapy to Target CD30 for Hodgkin Lymphoma – Drug Profile
Gene Therapy to Target CD30 for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma – Drug Profile
Gene Therapy to Target CD30 for Hodgkin Lymphoma and Peripheral T-Cell Lymphoma – Drug Profile
Gene Therapy to Target CD30 for Hodgkin''s Lymphoma – Drug Profile
Gene Therapy to Target CD30 for Lymphoproliferative Disorders – Drug Profile
Gene Therapy to Target CD30 for Oncology – Drug Profile
Gene Therapy to Target GM-CSF for Chronic Lymphocytic Leukemia and Hodgkin Lymphoma – Drug Profile
Gene Therapy to Target LMP1 for Epstein–Barr Virus (HHV-4) Infections and Oncology – Drug Profile
Gene-Modified Cell Therapy to Target CD30 for Oncology – Drug Profile
geptanolimab – Drug Profile
GRC-54276 – Drug Profile
HRAIN-009 – Drug Profile
HSC-100 – Drug Profile
HX-009 – Drug Profile
iberdomide hydrochloride – Drug Profile
ibrutinib – Drug Profile
IMM-01 – Drug Profile
IMMU-140 – Drug Profile
INBRX-105 – Drug Profile
iopofosine i-131 – Drug Profile
ipilimumab – Drug Profile
ipilimumab + nivolumab – Drug Profile
itacitinib adipate – Drug Profile
ixazomib citrate – Drug Profile
JS-004 – Drug Profile
JS-105 – Drug Profile
KLA-167 – Drug Profile
KT-333 – Drug Profile
LCB-71 – Drug Profile
LMP-400 – Drug Profile
magrolimab – Drug Profile
MEN-1703 – Drug Profile
MK-4280 – Drug Profile
mocetinostat – Drug Profile
Monoclonal Antibody Conjugate to Target TNFRSF8 for Oncology – Drug Profile
Monoclonal Antibody to Inhibit TIM-3 for Oncology – Drug Profile
nanatinostat – Drug Profile
NBT-528 – Drug Profile
nivolumab – Drug Profile
nivolumab biosimilar – Drug Profile
NTLA-6001 – Drug Profile
odronextamab – Drug Profile
olaparib – Drug Profile
OT-82 – Drug Profile
parsaclisib – Drug Profile
PCART-30 – Drug Profile
pembrolizumab – Drug Profile
pembrolizumab biosimilar – Drug Profile
PF-07901801 – Drug Profile
polatuzumab vedotin – Drug Profile
procarbazine hydrochloride – Drug Profile
racemetyrosine – Drug Profile
relatlimab – Drug Profile
ricolinostat – Drug Profile
RP-323 – Drug Profile
ruxolitinib phosphate – Drug Profile
SAR-444245 – Drug Profile
SEA-CD40 – Drug Profile
SENL-001 – Drug Profile
SG-2501 – Drug Profile
SGN-1 – Drug Profile
SGN-TGT – Drug Profile
sintilimab – Drug Profile
SL-279252 – Drug Profile
SL-501 – Drug Profile
Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma – Drug Profile
spanlecortemlocel – Drug Profile
subasumstat – Drug Profile
sugemalimab – Drug Profile
tenalisib – Drug Profile
tinostamustine – Drug Profile
tislelizumab – Drug Profile
toripalimab – Drug Profile
Triplex – Drug Profile
troriluzole hydrochloride – Drug Profile
TT-11 – Drug Profile
TT-11X – Drug Profile
TTI-621 – Drug Profile
TUB-010 – Drug Profile
tucidinostat – Drug Profile
UCART-123 – Drug Profile
Vaccine for EBV Associated Nasopharyngeal Cancer and Hodgkin Lymphoma – Drug Profile
valemetostat – Drug Profile
vidutolimod – Drug Profile
VIP-943 – Drug Profile
vorinostat – Drug Profile
VSV-CD30 – Drug Profile
vudalimab – Drug Profile
zimberelimab – Drug Profile
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin's lymphoma
Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting
Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting
Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma
Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13
Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications
Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications
Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting
Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting
Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan
Aug 30, 2021: Ligand’s partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma
Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma
Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma
May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology
May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, “Off-the-Shelf” cell therapy, in patients with relapsed or refractory CD30-positive lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Universities/Institutes, 2022
Table 8: Products under Development by Companies, 2022
Table 9: Products under Development by Companies, 2022 (Contd..1)
Table 10: Products under Development by Companies, 2022 (Contd..2)
Table 11: Products under Development by Companies, 2022 (Contd..3)
Table 12: Products under Development by Companies, 2022 (Contd..4)
Table 13: Products under Development by Companies, 2022 (Contd..5)
Table 14: Products under Development by Companies, 2022 (Contd..6)
Table 15: Products under Development by Companies, 2022 (Contd..7)
Table 16: Products under Development by Universities/Institutes, 2022
Table 17: Number of Products by Stage and Target, 2022
Table 18: Number of Products by Stage and Target, 2022 (Contd..1)
Table 19: Number of Products by Stage and Target, 2022 (Contd..2)
Table 20: Number of Products by Stage and Target, 2022 (Contd..3)
Table 21: Number of Products by Stage and Mechanism of Action, 2022
Table 22: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 23: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Table 25: Number of Products by Stage and Route of Administration, 2022
Table 26: Number of Products by Stage and Molecule Type, 2022
Table 27: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Table 28: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, 2022
Table 29: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, 2022
Table 30: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
Table 31: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, 2022
Table 32: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfasigma SpA, 2022
Table 33: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, 2022
Table 34: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, 2022
Table 35: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, 2022
Table 36: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, 2022
Table 37: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, 2022
Table 38: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, 2022
Table 39: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bayer AG, 2022
Table 40: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, 2022
Table 41: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bio-Path Holdings Inc, 2022
Table 42: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Table 43: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, 2022
Table 44: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, 2022
Table 45: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, 2022
Table 46: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, 2022
Table 47: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, 2022
Table 48: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, 2022
Table 49: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, 2022
Table 50: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, 2022
Table 51: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, 2022
Table 52: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, 2022
Table 53: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, 2022
Table 54: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chimeric Therapeutics Ltd, 2022
Table 55: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, 2022
Table 56: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Table 57: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, 2022
Table 58: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 59: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Dyadic International Inc, 2022
Table 60: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, 2022
Table 61: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, 2022
Table 62: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Genentech USA Inc, 2022
Table 63: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, 2022
Table 64: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gilead Sciences Inc, 2022
Table 65: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Table 66: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
Table 67: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022
Table 68: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Table 69: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
Table 70: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, 2022
Table 71: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, 2022
Table 72: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hutchison MediPharma Ltd, 2022
Table 73: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, 2022
Table 74: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
Table 75: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, 2022
Table 76: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, 2022
Table 77: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Innovent Biologics Inc, 2022
Table 78: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Intellia Therapeutics Inc, 2022
Table 79: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kymera Therapeutics Inc, 2022
Table 80: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by LegoChem Biosciences Inc, 2022
Table 81: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Luye Pharma Group Ltd, 2022
Table 82: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, 2022
Table 83: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, 2022
Table 84: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MediSix Therapeutics Pte Ltd, 2022
Table 85: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, 2022
Table 86: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, 2022
Table 87: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, 2022
Table 88: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Miltenyi Biotec BV & Co KG, 2022
Table 89: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, 2022
Table 90: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NewBio Therapeutics Inc, 2022
Table 91: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Northlake International LLC, 2022
Table 92: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by OncoTartis Inc, 2022
Table 93: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 94: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, 2022
Table 95: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by PlantForm Corp, 2022
Table 96: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Protheragen Inc, 2022
Table 97: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rafael Pharmaceuticals Inc, 2022
Table 98: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by RAPT Therapeutics Inc, 2022
Table 99: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 100: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, 2022
Table 101: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, 2022
Table 102: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Table 103: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sanofi, 2022
Table 104: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seagen Inc, 2022
Table 105: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022
Table 106: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Table 107: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Table 108: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Table 109: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
Table 110: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
Table 111: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
Table 112: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shattuck Labs Inc, 2022
Table 113: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Table 114: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Table 115: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by SpecificiT Pharma Inc, 2022
Table 116: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022
Table 117: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, 2022
Table 118: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tacitus Therapeutics Inc, 2022
Table 119: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 120: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tessa Therapeutics Ltd, 2022
Table 121: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tevogen Bio Inc, 2022
Table 122: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tubulis GmbH, 2022
Table 123: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Tyme Inc, 2022
Table 124: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Vincerx Pharma Inc, 2022
Table 125: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Viracta Therapeutics Inc, 2022
Table 126: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Waterstone Hanxbio Pty Ltd, 2022
Table 127: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Table 128: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Xencor Inc, 2022
Table 129: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022
Table 130: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..1)
Table 131: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..2)
Table 132: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..3)
Table 133: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, 2022 (Contd..4)
Table 134: Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings